Aphria Inc. (NYSE: APHA) has had what can be considered a tough go of it since it up-listed onto the New York Stock Exchange (NYSE) on November 2nd of this year. The value of APHA shares followed a similar trend that Aurora Cannabis Inc. (NYSE: ACB) faced when its shares also up-listed onto the NYSE and had share value continually decline.
The value of APHA, shortly after it listed onto the NYSE, increased by a little over 10% from $12 to $13.22 on November 7th. The gains for APHA stopped on the 7th and APHA share value would begin to decrease by an approximate 40.24% over the weeks until market close on November 30th at $7.90 per share.
On December 3rd APHA’s valuation was heavily influenced by the content within Hindenburg Research’s article on Aphria. Aphria responded two times to the short seller’s article through two press releases and stated within the initial response that the Hindenburg Research article is a “malicious and self-serving attempt to profit by manipulating Aphria’s stock price”.
APHA closed on December 3rd at $6.05 per share and closed to $4.51 per share on December 4th. The company’s close on December 4th is 62.42% less than the company’s IPO price of $12 and is a 42.92% decrease in value from APHA’s close on November 30th before the article was released.
The company’s second response on December 4th includes a comprehensive breakdown of every Latin American operation (LATAM). The thorough value breakdown includes all assets and current standings from Argentina, Colombia, and Jamaica. The Executive Management team concluded the second press release’s breakdown of all LATAM assets with a combined investment of $3.1 million into Aphria common shares.
Aphria’s Chief Executive officer, Vic Neufeld, said: “Yesterday, I, along with other members of our Executive Management team, stepped up to demonstrate our confidence in the Company’s business plan, growth strategy, integrity and value of the assets by personally investing more than $3.1 million in Aphria’s common shares.”
Learn more about cannabis-based pharma companies in the Cannin Report. Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll help you determine which cannabis companies to invest in.